(News Bulletin 247) – Credit Suisse maintains its Outperformance opinion on the Merck stock and its target price of $126.
‘Merck is preparing to present a series of data on advanced or metastatic lung cancer (NSCLC) from its phase 2 study evaluating MK-2870 as monotherapy in patients refractory to standard therapies’, notes the analyst.
Given the importance of unmet needs in the field of CPNPC 2L+, ‘Merck has the opportunity to conquer new market shares’, continues the broker.
However, Credit Suisse does not include the MK-2870 and ADCs from the Kelun collaboration in its forecast, but sees, ‘this initial data set as the first step towards de-risking its new ADC pipeline’.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
